Vaxcyte Inc saw a notable increase in its stock price, driven by positive market sentiment surrounding its upcoming clinical data readout.
Vaxcyte Inc (NASDAQ:PCVX) experienced a solid gain of 3.66% in its stock price yesterday, closing at CA$58.27. This upward movement can be attributed to investor optimism regarding the company's investigational pneumococcal conjugate vaccine, VAX-31, and its potential to validate broad coverage.
Advertisement
Vaxcyte Inc
PCVX.US
PCVX.US
Vaxcyte Inc
WealthAwesomeMarket cap
$8.67B
52W high
$65.00
52W low
$36.15
1W change
-1.10%
Beta
1.22
Analyst Price Targets
Based on 10 analysts covering PCVX · as of Sep 29, 2026
Wall Street analysts forecast PCVX stock price to rise 86.5% over the next 12 months.
Consensus
Strong Buy4.90 / 5.00
Avg. Target
C$108.67
+86.5% Upside
Previously C$109.00 on Sep 17, 2026
Current Price
C$58.27
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCVX's historical volatility
30-Day Vol
34.5%
Annualized
90-Day Vol
39.5%
Annualized
Trend (90d)
-0.9%
Annualized drift
90d Mean
C$58.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$58.21 | C$51.69 – C$65.56 |
| 60 trading days | C$58.15 | C$49.15 – C$68.80 |
| 90 trading days | C$58.09 | C$47.28 – C$71.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: With the upcoming data readout for VAX-31, investors are closely watching Vaxcyte's progress, as successful results could significantly enhance the company's market position and valuation.
Market Cap Reaches CA$8.67 Billion
Vaxcyte's market capitalization of CA$8.67 billion reflects strong investor interest and confidence in its innovative vaccine pipeline.
Bull case
If Vaxcyte's VAX-31 shows strong efficacy and safety in the upcoming trials, demand for the vaccine could rise, leading to increased revenue and market share.
Bear case
On the other hand, any negative results from the clinical trials could shake investor confidence and cause a significant drop in stock price, as the market reevaluates the company's pipeline and future prospects.
Advertisement
Positive Market Sentiment
Vaxcyte's stock price increase was largely influenced by recent analyst coverage, particularly from BofA, which highlighted the potential of VAX-31 to validate broad coverage against pneumococcal diseases. This optimism has been reflected in the stock's performance as investors anticipate favorable clinical data.
Upcoming Clinical Data Readout
The company is preparing to release critical safety and efficacy data for VAX-31, which could serve as a significant inflection point for its valuation. Investors are keenly aware that successful results could not only enhance Vaxcyte's reputation but also its financial outlook in the competitive vaccine market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
